A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
- Status
- RECRUITING
- Phase
- PHASE4
FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE2
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Status
- RECRUITING
- Phase
- PHASE2
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
- Status
- SUSPENDED
- Phase
- PHASE2
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- Status
- RECRUITING
- Phase
- PHASE3
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)
- Status
- RECRUITING
- Phase
- PHASE2
Autophagy Maintenance (AUTOMAIN)
- Status
- RECRUITING
- Phase
- PHASE2
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE3